Fig. 2.

Cumulative incidence of immune response, or the measure of immune response over time, over first 8 weeks of the trial period. a Includes all study participants by age grouping participants into either younger or older than 64 years, b uses only participants within the high-responder arms (Mel 43 without GM-CSF and Mel 44 with 6MHP) stratifying by age, c all study participants by gender, d includes only female patients and further stratifies them into younger or older than 50 years of age to approximate for menopause